Clinical, GH response to GHRH and Arg compared to Arg, and insulin and MRI findings in the adults with congenital hypopituitarism at the time of reevaluation
| Case no./Sex . | Age (yr) . | HT (sd score)/HT/reevalutation . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arg . | Insulin . | GHRH plus Arg . | ||||||
| 1/F | 16.9 | −0.4 | 75 | 0.7 | 2.2 | 7.3 | GH | VPS |
| 2/M | 19.9 | −0.4 | 113 | 0.9 | 1.4 | 19.5 | GH | VPS |
| 3/M | 18.0 | −2.2 | 87 | 0.4 | 0.6 | 4.0 | GH | VPS |
| 4/M | 19.9 | −3.4 | 66 | 1.9 | 0.1 | 37.4 | GH | VPS |
| 5/F | 16.8 | 1.0 | 102 | 2.1 | 2.1 | 19.4 | GH | VPS |
| 6/M | 15.9 | −1.6 | 71 | 2.3 | 1.3 | 4.6 | GH | VPS |
| 7/F | 16.7 | −4.7 | 61 | 1 | 1.5 | 3.3 | GH | VPS |
| 8/F | 26.0 | −3.5 | 67 | 0.6 | 0.5 | 1.6 | GH+FSH+LH | VPS |
| 9/M | 18.0 | −1.8 | 88 | 2.1 | 2.3 | 7.6 | GH+FSH+LH | VPS |
| 13/M | 28.6 | −0.4 | 33 | 0.5 | 0.1 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 14/M | 19.8 | −1.4 | 72 | 0.6 | 0.9 | 0.8 | GH+TSH+FSH+LH+ACTH | PSA |
| 15/M | 21.2 | −2.2 | 34 | 0.2 | 0.1 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 16/M | 24.4 | −2.7 | 54 | 0.6 | 0.5 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 10/F | 25.0 | 0.4 | 33 | 1.1 | 0.1 | 1.2 | GH+TSH+FSH+LH | PSA |
| 11/M | 21.9 | −1.6 | 54 | 1.1 | 0.5 | 2.1 | GH+TSH+FSH+LH | PSA |
| 17/M | 18.7 | −1.7 | 54 | 2.2 | 1.8 | 0.9 | GH+TSH+FSH+LH+ACTH | PSA |
| 18/F | 21.5 | −0.9 | 49 | 0.6 | 1.4 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 12/M | 19.4 | −2.6 | 53 | 0.7 | 1.5 | 1.8 | GH+TSH+FSH+LH | PSA |
| 19/M | 21.0 | −3.3 | 41 | 0.7 | 1.7 | 1.8 | GH+TSH+FSH+LH+ACTH | PSA |
| Case no./Sex . | Age (yr) . | HT (sd score)/HT/reevalutation . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arg . | Insulin . | GHRH plus Arg . | ||||||
| 1/F | 16.9 | −0.4 | 75 | 0.7 | 2.2 | 7.3 | GH | VPS |
| 2/M | 19.9 | −0.4 | 113 | 0.9 | 1.4 | 19.5 | GH | VPS |
| 3/M | 18.0 | −2.2 | 87 | 0.4 | 0.6 | 4.0 | GH | VPS |
| 4/M | 19.9 | −3.4 | 66 | 1.9 | 0.1 | 37.4 | GH | VPS |
| 5/F | 16.8 | 1.0 | 102 | 2.1 | 2.1 | 19.4 | GH | VPS |
| 6/M | 15.9 | −1.6 | 71 | 2.3 | 1.3 | 4.6 | GH | VPS |
| 7/F | 16.7 | −4.7 | 61 | 1 | 1.5 | 3.3 | GH | VPS |
| 8/F | 26.0 | −3.5 | 67 | 0.6 | 0.5 | 1.6 | GH+FSH+LH | VPS |
| 9/M | 18.0 | −1.8 | 88 | 2.1 | 2.3 | 7.6 | GH+FSH+LH | VPS |
| 13/M | 28.6 | −0.4 | 33 | 0.5 | 0.1 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 14/M | 19.8 | −1.4 | 72 | 0.6 | 0.9 | 0.8 | GH+TSH+FSH+LH+ACTH | PSA |
| 15/M | 21.2 | −2.2 | 34 | 0.2 | 0.1 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 16/M | 24.4 | −2.7 | 54 | 0.6 | 0.5 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 10/F | 25.0 | 0.4 | 33 | 1.1 | 0.1 | 1.2 | GH+TSH+FSH+LH | PSA |
| 11/M | 21.9 | −1.6 | 54 | 1.1 | 0.5 | 2.1 | GH+TSH+FSH+LH | PSA |
| 17/M | 18.7 | −1.7 | 54 | 2.2 | 1.8 | 0.9 | GH+TSH+FSH+LH+ACTH | PSA |
| 18/F | 21.5 | −0.9 | 49 | 0.6 | 1.4 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 12/M | 19.4 | −2.6 | 53 | 0.7 | 1.5 | 1.8 | GH+TSH+FSH+LH | PSA |
| 19/M | 21.0 | −3.3 | 41 | 0.7 | 1.7 | 1.8 | GH+TSH+FSH+LH+ACTH | PSA |
VPS, Vascular pituitary stalk; PSA, pituitary stalk agenesis. All patients were been treated with GH replacement during childhood.
Clinical, GH response to GHRH and Arg compared to Arg, and insulin and MRI findings in the adults with congenital hypopituitarism at the time of reevaluation
| Case no./Sex . | Age (yr) . | HT (sd score)/HT/reevalutation . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arg . | Insulin . | GHRH plus Arg . | ||||||
| 1/F | 16.9 | −0.4 | 75 | 0.7 | 2.2 | 7.3 | GH | VPS |
| 2/M | 19.9 | −0.4 | 113 | 0.9 | 1.4 | 19.5 | GH | VPS |
| 3/M | 18.0 | −2.2 | 87 | 0.4 | 0.6 | 4.0 | GH | VPS |
| 4/M | 19.9 | −3.4 | 66 | 1.9 | 0.1 | 37.4 | GH | VPS |
| 5/F | 16.8 | 1.0 | 102 | 2.1 | 2.1 | 19.4 | GH | VPS |
| 6/M | 15.9 | −1.6 | 71 | 2.3 | 1.3 | 4.6 | GH | VPS |
| 7/F | 16.7 | −4.7 | 61 | 1 | 1.5 | 3.3 | GH | VPS |
| 8/F | 26.0 | −3.5 | 67 | 0.6 | 0.5 | 1.6 | GH+FSH+LH | VPS |
| 9/M | 18.0 | −1.8 | 88 | 2.1 | 2.3 | 7.6 | GH+FSH+LH | VPS |
| 13/M | 28.6 | −0.4 | 33 | 0.5 | 0.1 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 14/M | 19.8 | −1.4 | 72 | 0.6 | 0.9 | 0.8 | GH+TSH+FSH+LH+ACTH | PSA |
| 15/M | 21.2 | −2.2 | 34 | 0.2 | 0.1 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 16/M | 24.4 | −2.7 | 54 | 0.6 | 0.5 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 10/F | 25.0 | 0.4 | 33 | 1.1 | 0.1 | 1.2 | GH+TSH+FSH+LH | PSA |
| 11/M | 21.9 | −1.6 | 54 | 1.1 | 0.5 | 2.1 | GH+TSH+FSH+LH | PSA |
| 17/M | 18.7 | −1.7 | 54 | 2.2 | 1.8 | 0.9 | GH+TSH+FSH+LH+ACTH | PSA |
| 18/F | 21.5 | −0.9 | 49 | 0.6 | 1.4 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 12/M | 19.4 | −2.6 | 53 | 0.7 | 1.5 | 1.8 | GH+TSH+FSH+LH | PSA |
| 19/M | 21.0 | −3.3 | 41 | 0.7 | 1.7 | 1.8 | GH+TSH+FSH+LH+ACTH | PSA |
| Case no./Sex . | Age (yr) . | HT (sd score)/HT/reevalutation . | IGF-I (μg/L) . | GH peak (μg/L) . | Associated hormone deficiencies . | MRI findings . | ||
|---|---|---|---|---|---|---|---|---|
| Arg . | Insulin . | GHRH plus Arg . | ||||||
| 1/F | 16.9 | −0.4 | 75 | 0.7 | 2.2 | 7.3 | GH | VPS |
| 2/M | 19.9 | −0.4 | 113 | 0.9 | 1.4 | 19.5 | GH | VPS |
| 3/M | 18.0 | −2.2 | 87 | 0.4 | 0.6 | 4.0 | GH | VPS |
| 4/M | 19.9 | −3.4 | 66 | 1.9 | 0.1 | 37.4 | GH | VPS |
| 5/F | 16.8 | 1.0 | 102 | 2.1 | 2.1 | 19.4 | GH | VPS |
| 6/M | 15.9 | −1.6 | 71 | 2.3 | 1.3 | 4.6 | GH | VPS |
| 7/F | 16.7 | −4.7 | 61 | 1 | 1.5 | 3.3 | GH | VPS |
| 8/F | 26.0 | −3.5 | 67 | 0.6 | 0.5 | 1.6 | GH+FSH+LH | VPS |
| 9/M | 18.0 | −1.8 | 88 | 2.1 | 2.3 | 7.6 | GH+FSH+LH | VPS |
| 13/M | 28.6 | −0.4 | 33 | 0.5 | 0.1 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 14/M | 19.8 | −1.4 | 72 | 0.6 | 0.9 | 0.8 | GH+TSH+FSH+LH+ACTH | PSA |
| 15/M | 21.2 | −2.2 | 34 | 0.2 | 0.1 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 16/M | 24.4 | −2.7 | 54 | 0.6 | 0.5 | 1.3 | GH+TSH+FSH+LH+ACTH | PSA |
| 10/F | 25.0 | 0.4 | 33 | 1.1 | 0.1 | 1.2 | GH+TSH+FSH+LH | PSA |
| 11/M | 21.9 | −1.6 | 54 | 1.1 | 0.5 | 2.1 | GH+TSH+FSH+LH | PSA |
| 17/M | 18.7 | −1.7 | 54 | 2.2 | 1.8 | 0.9 | GH+TSH+FSH+LH+ACTH | PSA |
| 18/F | 21.5 | −0.9 | 49 | 0.6 | 1.4 | 1.1 | GH+TSH+FSH+LH+ACTH | PSA |
| 12/M | 19.4 | −2.6 | 53 | 0.7 | 1.5 | 1.8 | GH+TSH+FSH+LH | PSA |
| 19/M | 21.0 | −3.3 | 41 | 0.7 | 1.7 | 1.8 | GH+TSH+FSH+LH+ACTH | PSA |
VPS, Vascular pituitary stalk; PSA, pituitary stalk agenesis. All patients were been treated with GH replacement during childhood.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
